Hormone replacement therapy and risk of breast cancer: the role of progestins

Epidemiological studies have shown an increased risk of breast cancer associated with the use of hormone replacement therapy (HRT). This notion is mostly based on studies from the USA. During the last decades unopposed estrogen treatment has been used to a lesser extent, whereas the combined estrogen‐progestin treatment regimen is now prescribed worldwide. In the USA the predominant compounds are conjugated estrogens and medroxyprogesterone‐acetate, whereas oestradiol combined with testosterone‐like progestins is commonly used in Europe. These differences are mainly the result of traditions. Recent studies originating from both the USA and Europe suggest that the combined treatment regimens with estrogen and progestin increase the risk of breast cancer beyond the risk following the use of unopposed estrogen. At present it is not known if progestins with different androgenecity influence the risk of breast cancer to a varying degree.

[1]  E. Weiderpass,et al.  Risks of breast and endometrial cancer after estrogen and estrogen–progestin replacement , 1999, Cancer Causes & Control.

[2]  J. Eden Progestins and breast cancer. , 2003, American journal of obstetrics and gynecology.

[3]  M. C. Terek,et al.  Mammographic density changes during different postmenopausal hormone replacement therapies. , 2001, Fertility and sterility.

[4]  J. Flaws,et al.  Hormone Replacement Therapy and Breast Cancer: A Qualitative Review , 2001, Obstetrics and gynecology.

[5]  H. Olsson,et al.  A population-based cohort study of HRT use and breast cancer in southern Sweden , 2001, British Journal of Cancer.

[6]  S. Hunskaar,et al.  Increased acceptance of HRT and improved level of information: a change in Norwegian women's opinion from 1990 to 1997 , 2001, Acta obstetricia et gynecologica Scandinavica.

[7]  S. Haslam,et al.  Estrogen and estrogen plus progestin act directly on the mammary gland to increase proliferation in a postmenopausal mouse model , 2001, Journal of cellular physiology.

[8]  T. Bush,et al.  Re: effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. , 2000, Journal of the National Cancer Institute.

[9]  G. Colditz,et al.  Cumulative risk of breast cancer to age 70 years according to risk factor status: data from the Nurses' Health Study. , 2000, American journal of epidemiology.

[10]  H. Adami,et al.  More about: effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. , 2000, Journal of the National Cancer Institute.

[11]  M. Pike,et al.  Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. , 2000, Journal of the National Cancer Institute.

[12]  G. Berntsen,et al.  Hormone replacement therapy: knowledge, attitudes, self-reported use - and sales figures in Nordic women. , 2000, Maturitas.

[13]  R. Millikan,et al.  Menopausal hormones and breast cancer in a biracial population. , 2000, American journal of public health.

[14]  R. Hoover,et al.  Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. , 2000, JAMA.

[15]  C. Campagnoli,et al.  HRT and breast cancer risk: a clue for interpreting the available data. , 1999, Maturitas.

[16]  K. Heck,et al.  Hormone replacement therapy and breast cancer risk in a nationally representative cohort. , 1999, American journal of preventive medicine.

[17]  P. Kenemans,et al.  Hormonal prevention of breast cancer: proposal for a change in paradigm , 1999, British journal of obstetrics and gynaecology.

[18]  C. la Vecchia,et al.  Risk factors for breast cancer in women under 40 years. , 1999, European journal of cancer.

[19]  B. V. VON Schoultz,et al.  Mammographic breast density during hormone replacement therapy: differences according to treatment. , 1999, American journal of obstetrics and gynecology.

[20]  V. Beral,et al.  Hormone Replacement Therapy: Patient Education Crucial , 1999, The Lancet.

[21]  H. Adami,et al.  Breast‐cancer risk following long‐term oestrogen‐ and oestrogen‐progestin‐replacement therapy , 1999, International journal of cancer.

[22]  U. Bergman,et al.  Low use of long-term hormone replacement therapy in Denmark. , 1999, British journal of clinical pharmacology.

[23]  Linda Olson,et al.  Effects of Estrogen and EstrogenProgestin on Mammographic Parenchymal Density , 1999, Annals of Internal Medicine.

[24]  T. Lancaster,et al.  Hormone replacement therapy: patterns of use studied through British general practice computerized records. , 1999, Family practice.

[25]  J. Townsend,et al.  Hormone replacement therapy: assessment of present use, costs, and trends. , 1998, The British journal of general practice : the journal of the Royal College of General Practitioners.

[26]  Svend Kreiner,et al.  Hormone replacement therapy and risk of non-fatal stroke , 1997, The Lancet.

[27]  Julian Peto,et al.  Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer , 1997, The Lancet.

[28]  H. Mouridsen,et al.  Time since childbirth and prognosis in primary breast cancer: population based study , 1997, BMJ.

[29]  K. Horwitz,et al.  Biphasic regulation of breast cancer cell growth by progesterone: role of the cyclin-dependent kinase inhibitors, p21 and p27(Kip1). , 1997, Molecular endocrinology.

[30]  D. Ciocca,et al.  Estrogen Receptors and Cell Proliferation in Breast Cancer , 1997, Trends in Endocrinology & Metabolism.

[31]  I Persson,et al.  Effect of estrogen and estrogen-progestin replacement regimens on mammographic breast parenchymal density. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  L. Holmberg,et al.  Hormone replacement therapy and the risk of breast cancer. Nested case‐control study in a cohort of Swedish women attending mammography screening , 1997, International journal of cancer.

[33]  L. Mattsson,et al.  The prevalence and severity of climacteric symptoms and the use of different treatment regimens in a Swedish population , 1997, Acta obstetricia et gynecologica Scandinavica.

[34]  J. Madans,et al.  Use of postmenopausal hormone replacement therapy: estimates from a nationally representative cohort study. , 1997, American journal of epidemiology.

[35]  Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer. , 1997, Lancet.

[36]  H. Schneider,et al.  Cross-national study of women's use of hormone replacement therapy (HRT) in Europe. , 1997, International journal of fertility and women's medicine.

[37]  F. Olesen,et al.  A comparative study of prescribing of hormone replacement therapy in USA and Europe. , 1996, Maturitas.

[38]  A. Holte,et al.  Trends in the use of climacteric and postclimacteric hormones in Nordic countries. , 1995, Maturitas.

[39]  A. Miller,et al.  Quantitative classification of mammographic densities and breast cancer risk: results from the Canadian National Breast Screening Study. , 1995, Journal of the National Cancer Institute.

[40]  J. Russo,et al.  The etiopathogenesis of breast cancer prevention. , 1995, Cancer letters.

[41]  H. Adami,et al.  Transient increase in the risk of breast cancer after giving birth. , 1994, The New England journal of medicine.

[42]  R. Dickson,et al.  Progestins and antiprogestins in mammary tumour growth and metastasis. , 1994, Human reproduction.

[43]  G. Colditz,et al.  Hormone replacement therapy and risk of breast cancer: results from epidemiologic studies. , 1993, American journal of obstetrics and gynecology.

[44]  M. Pike,et al.  Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk. , 1993, Epidemiologic reviews.

[45]  S. Thacker,et al.  A meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer. , 1991, JAMA.

[46]  C. Clarke,et al.  Progestin regulation of cellular proliferation. , 1990, Endocrine reviews.

[47]  M. Ewertz Influence of non‐contraceptive exogenous and endogenous sex hormones on breast cancer risk in Denmark , 1988, International journal of cancer.

[48]  S. Kjaer,et al.  Ovarian cancer incidence and mortality in denmark, 1943‐1982 , 1988, International journal of cancer.

[49]  T. Longacre,et al.  A Correlative Morphologic Study of Human Breast and Endometrium in the Menstrual Cycle , 1986, The American journal of surgical pathology.